2.1
Sodium zirconium cyclosilicate (Lokelma, AstraZeneca) is indicated for 'the treatment of hyperkalaemia in adult patients'.
Closed for comments This consultation ended on at Request commenting lead permission
Sodium zirconium cyclosilicate (Lokelma, AstraZeneca) is indicated for 'the treatment of hyperkalaemia in adult patients'.
The dosage schedule is available in the summary of product characteristics for sodium zirconium cyclosilicate.
The list price of sodium zirconium cyclosilicate is £10.40 per 10-g sachet or £5.20 per 5-g sachet (BNF, October 2025)
Costs may vary in different settings because of negotiated procurement discounts.
Information on the Carbon Reduction Plan for UK carbon emissions for AstraZeneca will be included here when guidance is published.
How are you taking part in this consultation?
You will not be able to change how you comment later.
You must be signed in to answer questions
Question on Consultation
Question on Consultation
Question on Consultation
Question on Consultation